

# Jorge Cortes

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/11531546/publications.pdf>

Version: 2024-02-01

387  
papers

51,171  
citations

872

117  
h-index

1676

214  
g-index

399  
all docs

399  
docs citations

399  
times ranked

24782  
citing authors

#	ARTICLE	IF	CITATIONS
1	Dasatinib in Imatinib-Resistant Philadelphia Chromosome-Positive Leukemias. <i>New England Journal of Medicine</i> , 2006, 354, 2531-2541.	27.0	1,606
2	Dasatinib versus Imatinib in Newly Diagnosed Chronic-Phase Chronic Myeloid Leukemia. <i>New England Journal of Medicine</i> , 2010, 362, 2260-2270.	27.0	1,411
3	Nilotinib in Imatinib-Resistant CML and Philadelphia Chromosome-Positive ALL. <i>New England Journal of Medicine</i> , 2006, 354, 2542-2551.	27.0	1,253
4	Chronic Myeloid Leukemia: An Update of Concepts and Management Recommendations of European LeukemiaNet. <i>Journal of Clinical Oncology</i> , 2009, 27, 6041-6051.	1.6	1,188
5	Evolving concepts in the management of chronic myeloid leukemia: recommendations from an expert panel on behalf of the European LeukemiaNet. <i>Blood</i> , 2006, 108, 1809-1820.	1.4	1,184
6	Monitoring CML patients responding to treatment with tyrosine kinase inhibitors: review and recommendations for harmonizing current methodology for detecting BCR-ABL transcripts and kinase domain mutations and for expressing results. <i>Blood</i> , 2006, 108, 28-37.	1.4	1,117
7	Early Results of a Chemoimmunotherapy Regimen of Fludarabine, Cyclophosphamide, and Rituximab As Initial Therapy for Chronic Lymphocytic Leukemia. <i>Journal of Clinical Oncology</i> , 2005, 23, 4079-4088.	1.6	899
8	Phase 1 study of low-dose prolonged exposure schedules of the hypomethylating agent 5-aza-2'-deoxycytidine (decitabine) in hematopoietic malignancies. <i>Blood</i> , 2004, 103, 1635-1640.	1.4	783
9	Results of Treatment With Hyper-CVAD, a Dose-Intensive Regimen, in Adult Acute Lymphocytic Leukemia. <i>Journal of Clinical Oncology</i> , 2000, 18, 547-547.	1.6	706
10	Results of a randomized study of 3 schedules of low-dose decitabine in higher-risk myelodysplastic syndrome and chronic myelomonocytic leukemia. <i>Blood</i> , 2007, 109, 52-57.	1.4	675
11	Human chronic myeloid leukemia stem cells are insensitive to imatinib despite inhibition of BCR-ABL activity. <i>Journal of Clinical Investigation</i> , 2011, 121, 396-409.	8.2	661
12	Long-term results of the fludarabine, cyclophosphamide, and rituximab regimen as initial therapy of chronic lymphocytic leukemia. <i>Blood</i> , 2008, 112, 975-980.	1.4	638
13	Molecular biology of bcr-abl1-positive chronic myeloid leukemia. <i>Blood</i> , 2009, 113, 1619-1630.	1.4	591
14	Rituximab Dose-Escalation Trial in Chronic Lymphocytic Leukemia. <i>Journal of Clinical Oncology</i> , 2001, 19, 2165-2170.	1.6	572
15	Selective BCL-2 Inhibition by ABT-199 Causes On-Target Cell Death in Acute Myeloid Leukemia. <i>Cancer Discovery</i> , 2014, 4, 362-375.	9.4	561
16	Long-term follow-up results of hyperfractionated cyclophosphamide, vincristine, doxorubicin, and dexamethasone (Hyper-CVAD), a dose-intensive regimen, in adult acute lymphocytic leukemia. <i>Cancer</i> , 2004, 101, 2788-2801.	4.1	550
17	Treatment of Philadelphia chromosome-positive acute lymphocytic leukemia with hyper-CVAD and imatinib mesylate. <i>Blood</i> , 2004, 103, 4396-4407.	1.4	522
18	miR-328 Functions as an RNA Decoy to Modulate hnRNP E2 Regulation of mRNA Translation in Leukemic Blasts. <i>Cell</i> , 2010, 140, 652-665.	28.9	514

#	ARTICLE	IF	CITATIONS
19	Chemoimmunotherapy with hyper-CVAD plus rituximab for the treatment of adult Burkitt and Burkitt-type lymphoma or acute lymphoblastic leukemia. <i>Cancer</i> , 2006, 106, 1569-1580.	4.1	503
20	Phase 1/2 study of the combination of 5-aza-2'-deoxycytidine with valproic acid in patients with leukemia. <i>Blood</i> , 2006, 108, 3271-3279.	1.4	492
21	Chemoimmunotherapy With Fludarabine, Cyclophosphamide, and Rituximab for Relapsed and Refractory Chronic Lymphocytic Leukemia. <i>Journal of Clinical Oncology</i> , 2005, 23, 4070-4078.	1.6	480
22	Proposal for a new risk model in myelodysplastic syndrome that accounts for events not considered in the original International Prognostic Scoring System. <i>Cancer</i> , 2008, 113, 1351-1361.	4.1	458
23	Phase 1 study of the histone deacetylase inhibitor vorinostat (suberoylanilide hydroxamic acid) in patients with relapsed or refractory acute myeloid leukemia. <i>Blood</i> , 2008, 112, 1074-1081.	1.4	440
24	Selective inhibition of FLT3 by gilteritinib in relapsed or refractory acute myeloid leukaemia: a multicentre, first-in-human, open-label, phase 1a/2 study. <i>Lancet Oncology</i> , 2017, 18, 1061-1075.	10.7	402
25	Inotuzumab ozogamicin, an anti-CD22 antibody-drug conjugate, for refractory and relapsed acute lymphocytic leukaemia: a phase 2 study. <i>Lancet Oncology</i> , 2012, 13, 403-411.	10.7	401
26	Dasatinib induces complete hematologic and cytogenetic responses in patients with imatinib-resistant or -intolerant chronic myeloid leukemia in blast crisis. <i>Blood</i> , 2007, 109, 3207-3213.	1.4	400
27	Safety and clinical activity of the combination of 5-azacytidine, valproic acid, and all-trans retinoic acid in acute myeloid leukemia and myelodysplastic syndrome. <i>Blood</i> , 2007, 110, 2302-2308.	1.4	391
28	High-dose imatinib mesylate therapy in newly diagnosed Philadelphia chromosome-positive chronic phase chronic myeloid leukemia. <i>Blood</i> , 2004, 103, 2873-2878.	1.4	369
29	Pegylated Interferon Alfa-2a Yields High Rates of Hematologic and Molecular Response in Patients With Advanced Essential Thrombocythemia and Polycythemia Vera. <i>Journal of Clinical Oncology</i> , 2009, 27, 5418-5424.	1.6	367
30	Early response with dasatinib or imatinib in chronic myeloid leukemia: 3-year follow-up from a randomized phase 3 trial (DASISION). <i>Blood</i> , 2014, 123, 494-500.	1.4	364
31	MK-0457, a novel kinase inhibitor, is active in patients with chronic myeloid leukemia or acute lymphocytic leukemia with the T315I BCR-ABL mutation. <i>Blood</i> , 2007, 109, 500-502.	1.4	363
32	Chemoimmunotherapy With a Modified Hyper-CVAD and Rituximab Regimen Improves Outcome in De Novo Philadelphia Chromosome-Negative Precursor B-Lineage Acute Lymphoblastic Leukemia. <i>Journal of Clinical Oncology</i> , 2010, 28, 3880-3889.	1.6	361
33	Phase 2 study of azacytidine plus sorafenib in patients with acute myeloid leukemia and FLT-3 internal tandem duplication mutation. <i>Blood</i> , 2013, 121, 4655-4662.	1.4	355
34	Pleural Effusion in Patients With Chronic Myelogenous Leukemia Treated With Dasatinib After Imatinib Failure. <i>Journal of Clinical Oncology</i> , 2007, 25, 3908-3914.	1.6	350
35	Nilotinib is effective in patients with chronic myeloid leukemia in chronic phase after imatinib resistance or intolerance: 24-month follow-up results. <i>Blood</i> , 2011, 117, 1141-1145.	1.4	344
36	Clinical experience with the BCL-2 inhibitor venetoclax in combination therapy for relapsed and refractory acute myeloid leukemia and related myeloid malignancies. <i>American Journal of Hematology</i> , 2018, 93, 401-407.	4.1	336

#	ARTICLE	IF	CITATIONS
37	Mutant FLT3: A Direct Target of Sorafenib in Acute Myelogenous Leukemia. <i>Journal of the National Cancer Institute</i> , 2008, 100, 184-198.	6.3	334
38	The effects of imatinib on pregnancy outcome. <i>Blood</i> , 2008, 111, 5505-5508.	1.4	328
39	Results of the Fludarabine and Cyclophosphamide Combination Regimen in Chronic Lymphocytic Leukemia. <i>Journal of Clinical Oncology</i> , 2001, 19, 1414-1420.	1.6	321
40	A Phase I Study of Intravenous LBH589, a Novel Cinnamic Hydroxamic Acid Analogue Histone Deacetylase Inhibitor, in Patients with Refractory Hematologic Malignancies. <i>Clinical Cancer Research</i> , 2006, 12, 4628-4635.	7.0	320
41	First report of phase 2 study of dasatinib with hyper-CVAD for the frontline treatment of patients with Philadelphia chromosome-positive (Ph+) acute lymphoblastic leukemia. <i>Blood</i> , 2010, 116, 2070-2077.	1.4	319
42	International Working Group (IWG) consensus criteria for treatment response in myelofibrosis with myeloid metaplasia, for the IWG for Myelofibrosis Research and Treatment (IWG-MRT). <i>Blood</i> , 2006, 108, 1497-1503.	1.4	317
43	Phase 2 clinical and pharmacologic study of clofarabine in patients with refractory or relapsed acute leukemia. <i>Blood</i> , 2003, 102, 2379-2386.	1.4	313
44	FTY720, a new alternative for treating blast crisis chronic myelogenous leukemia and Philadelphia chromosome-positive acute lymphocytic leukemia. <i>Journal of Clinical Investigation</i> , 2007, 117, 2408-2421.	8.2	308
45	Dose escalation of imatinib mesylate can overcome resistance to standard-dose therapy in patients with chronic myelogenous leukemia. <i>Blood</i> , 2003, 101, 473-475.	1.4	304
46	Prognostic nomogram and index for overall survival in previously untreated patients with chronic lymphocytic leukemia. <i>Blood</i> , 2007, 109, 4679-4685.	1.4	303
47	Improved survival in chronic myeloid leukemia since the introduction of imatinib therapy: a single-institution historical experience. <i>Blood</i> , 2012, 119, 1981-1987.	1.4	298
48	Impact of Baseline <i>BCR-ABL</i> Mutations on Response to Nilotinib in Patients With Chronic Myeloid Leukemia in Chronic Phase. <i>Journal of Clinical Oncology</i> , 2009, 27, 4204-4210.	1.6	292
49	Phase II Study of Low-Dose Decitabine in Patients With Chronic Myelogenous Leukemia Resistant to Imatinib Mesylate. <i>Journal of Clinical Oncology</i> , 2005, 23, 3948-3956.	1.6	290
50	Ph-like acute lymphoblastic leukemia: a high-risk subtype in adults. <i>Blood</i> , 2017, 129, 572-581.	1.4	285
51	Dynamics of <i>BCR-ABL</i> kinase domain mutations in chronic myeloid leukemia after sequential treatment with multiple tyrosine kinase inhibitors. <i>Blood</i> , 2007, 110, 4005-4011.	1.4	284
52	Nilotinib (formerly AMN107), a highly selective <i>BCR-ABL</i> tyrosine kinase inhibitor, is active in patients with imatinib-resistant or -intolerant accelerated-phase chronic myelogenous leukemia. <i>Blood</i> , 2008, 111, 1834-1839.	1.4	284
53	Imatinib mesylate (STI571) therapy for Philadelphia chromosome-positive chronic myelogenous leukemia in blast phase. <i>Blood</i> , 2002, 99, 3547-3553.	1.4	282
54	Flying under the radar: the new wave of <i>BCR-ABL</i> inhibitors. <i>Nature Reviews Drug Discovery</i> , 2007, 6, 834-848.	46.4	272

#	ARTICLE	IF	CITATIONS
55	Discontinuation of imatinib therapy after achieving a molecular response. <i>Blood</i> , 2004, 104, 2204-2205.	1.4	270
56	Results of inotuzumab ozogamicin, a CD22 monoclonal antibody, in refractory and relapsed acute lymphocytic leukemia. <i>Cancer</i> , 2013, 119, 2728-2736.	4.1	265
57	Janus kinase inhibitors for the treatment of myeloproliferative neoplasias and beyond. <i>Nature Reviews Drug Discovery</i> , 2011, 10, 127-140.	46.4	261
58	Tyrosine kinase inhibitor discontinuation in patients with chronic myeloid leukemia: a single-institution experience. <i>Journal of Hematology and Oncology</i> , 2019, 12, 1.	17.0	257
59	Molecular Responses in Patients with Chronic Myelogenous Leukemia in Chronic Phase Treated with Imatinib Mesylate. <i>Clinical Cancer Research</i> , 2005, 11, 3425-3432.	7.0	256
60	Experience with alemtuzumab plus rituximab in patients with relapsed and refractory lymphoid malignancies. <i>Blood</i> , 2003, 101, 3413-3415.	1.4	247
61	Combination of hyper-CVAD with ponatinib as first-line therapy for patients with Philadelphia chromosome-positive acute lymphoblastic leukaemia: a single-centre, phase 2 study. <i>Lancet Oncology</i> , 2015, 16, 1547-1555.	10.7	245
62	Estimations of the increasing prevalence and plateau prevalence of chronic myeloid leukemia in the era of tyrosine kinase inhibitor therapy. <i>Cancer</i> , 2012, 118, 3123-3127.	4.1	243
63	Hyper-CVAD Program in Burkitt's-Type Adult Acute Lymphoblastic Leukemia. <i>Journal of Clinical Oncology</i> , 1999, 17, 2461-2461.	1.6	242
64	Outcome of patients with myelodysplastic syndrome after failure of decitabine therapy. <i>Cancer</i> , 2010, 116, 3830-3834.	4.1	241
65	Congestive heart failure is a rare event in patients receiving imatinib therapy. <i>Blood</i> , 2007, 110, 1233-1237.	1.4	233
66	Outcome with the hyper-CVAD regimens in lymphoblastic lymphoma. <i>Blood</i> , 2004, 104, 1624-1630.	1.4	231
67	Results of decitabine (5-azadeoxycytidine) therapy in 130 patients with chronic myelogenous leukemia. <i>Cancer</i> , 2003, 98, 522-528.	4.1	230
68	Phase 1 study of the oral isotype specific histone deacetylase inhibitor MGCD0103 in leukemia. <i>Blood</i> , 2008, 112, 981-989.	1.4	229
69	New Insights into the Pathophysiology of Chronic Myeloid Leukemia and Imatinib Resistance. <i>Annals of Internal Medicine</i> , 2006, 145, 913.	3.9	216
70	Results of a phase 1-2 study of clofarabine in combination with cytarabine (ara-C) in relapsed and refractory acute leukemias. <i>Blood</i> , 2005, 105, 940-947.	1.4	213
71	Pregnancy Among Patients With Chronic Myeloid Leukemia Treated With Imatinib. <i>Journal of Clinical Oncology</i> , 2006, 24, 1204-1208.	1.6	210
72	Phase 2 study of CEP-701, an orally available JAK2 inhibitor, in patients with primary or post-polycythemia vera/essential thrombocythemia myelofibrosis. <i>Blood</i> , 2010, 115, 1131-1136.	1.4	210

#	ARTICLE	IF	CITATIONS
73	Survival benefit with imatinib mesylate versus interferon- $\gamma$ -based regimens in newly diagnosed chronic-phase chronic myelogenous leukemia. <i>Blood</i> , 2006, 108, 1835-1840.	1.4	204
74	Alemtuzumab as treatment for residual disease after chemotherapy in patients with chronic lymphocytic leukemia. <i>Cancer</i> , 2003, 98, 2657-2663.	4.1	203
75	AMN107, a Novel Aminopyrimidine Inhibitor of Bcr-Abl, Has In vitro Activity against Imatinib-Resistant Chronic Myeloid Leukemia. <i>Clinical Cancer Research</i> , 2005, 11, 4941-4947.	7.0	202
76	Favorable long-term follow-up results over 6 years for response, survival, and safety with imatinib mesylate therapy in chronic-phase chronic myeloid leukemia after failure of interferon- $\gamma$ treatment. <i>Blood</i> , 2008, 111, 1039-1043.	1.4	195
77	Dasatinib or high-dose imatinib for chronic-phase chronic myeloid leukemia resistant to imatinib at a dose of 400 to 600 milligrams daily. <i>Cancer</i> , 2009, 115, 4136-4147.	4.1	195
78	Epigenetic therapy is associated with similar survival compared with intensive chemotherapy in older patients with newly diagnosed acute myeloid leukemia. <i>Blood</i> , 2012, 120, 4840-4845.	1.4	193
79	PP2A-activating drugs selectively eradicate TKI-resistant chronic myeloid leukemic stem cells. <i>Journal of Clinical Investigation</i> , 2013, 123, 4144-4157.	8.2	192
80	Final report of a phase II study of imatinib mesylate with hyper-CVAD for the front-line treatment of adult patients with Philadelphia chromosome-positive acute lymphoblastic leukemia. <i>Haematologica</i> , 2015, 100, 653-661.	3.5	191
81	Combination of hyper-CVAD with ponatinib as first-line therapy for patients with Philadelphia chromosome-positive acute lymphoblastic leukaemia: long-term follow-up of a single-centre, phase 2 study. <i>Lancet Haematology</i> , 2018, 5, e618-e627.	4.6	190
82	Phase I Clinical and Pharmacology Study of Clofarabine in Patients With Solid and Hematologic Cancers. <i>Journal of Clinical Oncology</i> , 2003, 21, 1167-1173.	1.6	185
83	Molecular analysis of patients with polycythemia vera or essential thrombocythemia receiving pegylated interferon $\gamma$ -2a. <i>Blood</i> , 2013, 122, 893-901.	1.4	184
84	Survival advantage with decitabine versus intensive chemotherapy in patients with higher risk myelodysplastic syndrome. <i>Cancer</i> , 2007, 109, 1133-1137.	4.1	182
85	Primary refractory and relapsed adult acute lymphoblastic leukemia. , 1999, 86, 1216-1230.		178
86	Tyrosine kinase inhibitor-induced platelet dysfunction in patients with chronic myeloid leukemia. <i>Blood</i> , 2009, 114, 261-263.	1.4	178
87	Prognostic significance of CD20 expression in adults with de novo precursor B-lineage acute lymphoblastic leukemia. <i>Blood</i> , 2009, 113, 6330-6337.	1.4	175
88	Result of high-dose imatinib mesylate in patients with Philadelphia chromosome-positive chronic myeloid leukemia after failure of interferon- $\gamma$ . <i>Blood</i> , 2003, 102, 83-86.	1.4	174
89	Chronic myelogenous leukemia in nonlymphoid blastic phase. , 1999, 86, 2632-2641.		167
90	Chronic myeloid leukemia (CML) with P190BCR-ABL: analysis of characteristics, outcomes, and prognostic significance. <i>Blood</i> , 2009, 114, 2232-2235.	1.4	158

#	ARTICLE	IF	CITATIONS
91	Phase 3 study of dasatinib 140 mg once daily versus 70 mg twice daily in patients with chronic myeloid leukemia in accelerated phase resistant or intolerant to imatinib: 15-month median follow-up. <i>Blood</i> , 2009, 113, 6322-6329.	1.4	156
92	Rituximab in relapsed or refractory hairy cell leukemia. <i>Blood</i> , 2003, 102, 3906-3911.	1.4	155
93	Delayed achievement of cytogenetic and molecular response is associated with increased risk of progression among patients with chronic myeloid leukemia in early chronic phase receiving high-dose or standard-dose imatinib therapy. <i>Blood</i> , 2009, 113, 6315-6321.	1.4	153
94	Lenalidomide Plus Prednisone Results in Durable Clinical, Histopathologic, and Molecular Responses in Patients With Myelofibrosis. <i>Journal of Clinical Oncology</i> , 2009, 27, 4760-4766.	1.6	152
95	Phase II Study of Dasatinib in Philadelphia Chromosome-“Negative Acute and Chronic Myeloid Diseases, Including Systemic Mastocytosis. <i>Clinical Cancer Research</i> , 2008, 14, 3906-3915.	7.0	151
96	Imatinib mesylate dose escalation is associated with durable responses in patients with chronic myeloid leukemia after cytogenetic failure on standard-dose imatinib therapy. <i>Blood</i> , 2009, 113, 2154-2160.	1.4	151
97	Randomized phase 2 study of low-dose decitabine vs low-dose azacitidine in lower-risk MDS and MDS/MPN. <i>Blood</i> , 2017, 130, 1514-1522.	1.4	151
98	Dasatinib (BMS-354825) is active in Philadelphia chromosome-“positive chronic myelogenous leukemia after imatinib and nilotinib (AMN107) therapy failure. <i>Blood</i> , 2007, 109, 497-499.	1.4	150
99	Myelodysplastic syndromes and acute leukemia developing after imatinib mesylate therapy for chronic myeloid leukemia. <i>Blood</i> , 2006, 108, 2811-2813.	1.4	149
100	Hyperfractionated cyclophosphamide, vincristine, doxorubicin, and dexamethasone and highly active antiretroviral therapy for patients with acquired immunodeficiency syndrome-“related burkitt lymphoma/leukemia. <i>Cancer</i> , 2002, 94, 1492-1499.	4.1	146
101	Clofarabine and cytarabine combination as induction therapy for acute myeloid leukemia (AML) in patients 50 years of age or older. <i>Blood</i> , 2006, 108, 45-51.	1.4	146
102	Monitoring the response and course of chronic myeloid leukemia in the modern era of BCR-ABL tyrosine kinase inhibitors: practical advice on the use and interpretation of monitoring methods. <i>Blood</i> , 2008, 111, 1774-1780.	1.4	140
103	Phase I/II trial of the combination of midostaurin (PKC412) and 5-azacytidine for patients with acute myeloid leukemia and myelodysplastic syndrome. <i>American Journal of Hematology</i> , 2015, 90, 276-281.	4.1	139
104	Chromosomal abnormalities in Philadelphia chromosome-“negative metaphases appearing during imatinib mesylate therapy in patients with newly diagnosed chronic myeloid leukemia in chronic phase. <i>Blood</i> , 2007, 110, 2991-2995.	1.4	138
105	The use of nilotinib or dasatinib after failure to 2 prior tyrosine kinase inhibitors: long-term follow-up. <i>Blood</i> , 2009, 114, 4361-4368.	1.4	138
106	Treatment of Philadelphia Chromosome-Positive Early Chronic Phase Chronic Myelogenous Leukemia With Daily Doses of Interferon Alpha and Low-Dose Cytarabine. <i>Journal of Clinical Oncology</i> , 1999, 17, 284-284.	1.6	135
107	Phase II study of low-dose decitabine in combination with imatinib mesylate in patients with accelerated or myeloid blastic phase of chronic myelogenous leukemia. <i>Cancer</i> , 2007, 109, 899-906.	4.1	134
108	Outcome of Philadelphia Chromosome-Positive Adult Acute Lymphoblastic Leukemia. <i>Leukemia and Lymphoma</i> , 2000, 36, 263-273.	1.3	133

#	ARTICLE	IF	CITATIONS
109	The achievement of an early complete cytogenetic response is a major determinant for outcome in patients with early chronic phase chronic myeloid leukemia treated with tyrosine kinase inhibitors. <i>Blood</i> , 2011, 118, 4541-4546.	1.4	133
110	Combined targeting of BCL-2 and BCR-ABL tyrosine kinase eradicates chronic myeloid leukemia stem cells. <i>Science Translational Medicine</i> , 2016, 8, 355ra117.	12.4	130
111	Outcome of adults with acute lymphocytic leukemia after second salvage therapy. <i>Cancer</i> , 2008, 113, 3186-3191.	4.1	129
112	Characteristics and outcomes of patients with chronic myeloid leukemia and T315I mutation following failure of imatinib mesylate therapy. <i>Blood</i> , 2008, 112, 53-55.	1.4	127
113	Safety and Efficacy of Blinatumomab in Combination With a Tyrosine Kinase Inhibitor for the Treatment of Relapsed Philadelphia Chromosome-positive Leukemia. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2017, 17, 897-901.	0.4	127
114	Chromosomal abnormalities in Philadelphia chromosome-negative metaphases appearing during imatinib mesylate therapy in patients with Philadelphia chromosome-positive chronic myelogenous leukemia in chronic phase. <i>Cancer</i> , 2003, 98, 1905-1911.	4.1	124
115	Multivariable Model for Time to First Treatment in Patients With Chronic Lymphocytic Leukemia. <i>Journal of Clinical Oncology</i> , 2011, 29, 4088-4095.	1.6	124
116	Early responses predict better outcomes in patients with newly diagnosed chronic myeloid leukemia: results with four tyrosine kinase inhibitor modalities. <i>Blood</i> , 2013, 121, 4867-4874.	1.4	124
117	Salvage Chemoimmunotherapy With Inotuzumab Ozogamicin Combined With Mini-“Hyper-CVD for Patients With Relapsed or Refractory Philadelphia Chromosome-“Negative Acute Lymphoblastic Leukemia. <i>JAMA Oncology</i> , 2018, 4, 230.	7.1	124
118	Phase 2 study of subcutaneous omacetaxine mepesuccinate after TKI failure in patients with chronic-phase CML with T315I mutation. <i>Blood</i> , 2012, 120, 2573-2580.	1.4	123
119	Results of phase 2 randomized study of low-dose decitabine with or without valproic acid in patients with myelodysplastic syndrome and acute myelogenous leukemia. <i>Cancer</i> , 2015, 121, 556-561.	4.1	122
120	Phase I/II study of subcutaneous homoharringtonine in patients with chronic myeloid leukemia who have failed prior therapy. <i>Cancer</i> , 2007, 109, 248-255.	4.1	121
121	The prognosis for patients with chronic myeloid leukemia who have clonal cytogenetic abnormalities in philadelphia chromosome-“negative cells. <i>Cancer</i> , 2007, 110, 1509-1519.	4.1	121
122	Healthcare resource utilization and costs associated with non-adherence to imatinib treatment in chronic myeloid leukemia patients. <i>Current Medical Research and Opinion</i> , 2010, 26, 61-69.	1.9	121
123	Activity of decitabine, a hypomethylating agent, in chronic myelomonocytic leukemia. <i>Cancer</i> , 2007, 109, 713-717.	4.1	120
124	Imatinib and beyond-“exploring the full potential of targeted therapy for CML. <i>Nature Reviews Clinical Oncology</i> , 2009, 6, 535-543.	27.6	120
125	Use of Second- and Third-Generation Tyrosine Kinase Inhibitors in the Treatment of Chronic Myeloid Leukemia: An Evolving Treatment Paradigm. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2015, 15, 323-334.	0.4	120
126	Long-term outcome of patients with chronic myeloid leukemia treated with second-generation tyrosine kinase inhibitors after imatinib failure is predicted by the in vitro sensitivity of BCR-ABL kinase domain mutations. <i>Blood</i> , 2009, 114, 2037-2043.	1.4	119



#	ARTICLE	IF	CITATIONS
127	Impact of BCR-ABL transcript type on outcome in patients with chronic-phase CML treated with tyrosine kinase inhibitors. <i>Blood</i> , 2016, 127, 1269-1275.	1.4	119
128	Nilotinib-Associated Vascular Events. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2012, 12, 337-340.	0.4	118
129	Bleeding diathesis in patients with chronic myelogenous leukemia receiving dasatinib therapy. <i>Cancer</i> , 2009, 115, 2482-2490.	4.1	116
130	Dasatinib in imatinib-resistant or imatinib-intolerant chronic myeloid leukemia in blast phase after 2 years of follow-up in a phase 3 study. <i>Cancer</i> , 2010, 116, 3852-3861.	4.1	115
131	Homoharringtonine, omacetaxine mepesuccinate, and chronic myeloid leukemia circa 2009. <i>Cancer</i> , 2009, 115, 5382-5393.	4.1	114
132	Secondary mutations as mediators of resistance to targeted therapy in leukemia. <i>Blood</i> , 2015, 125, 3236-3245.	1.4	113
133	Clinical resistance to crenolanib in acute myeloid leukemia due to diverse molecular mechanisms. <i>Nature Communications</i> , 2019, 10, 244.	12.8	111
134	Fractionated cyclophosphamide, vincristine, liposomal daunorubicin, and dexamethasone plus rituximab and granulocyte-macrophage-colony stimulating factor (GM-CSF) alternating with methotrexate and cytarabine plus rituximab and GM-CSF in patients with Richter syndrome or fludarabine-refractory chronic lymphocytic leukemia. <i>Cancer</i> , 2003, 97, 1711-1720.	4.1	110
135	Epidemiologic study on survival of chronic myeloid leukemia and Ph+ acute lymphoblastic leukemia patients with BCR-ABL T315I mutation. <i>Blood</i> , 2009, 114, 5271-5278.	1.4	109
136	Efficacy of imatinib dose escalation in patients with chronic myeloid leukemia in chronic phase. <i>Cancer</i> , 2009, 115, 551-560.	4.1	108
137	Management of imatinib-resistant patients with chronic myeloid leukemia. <i>Therapeutic Advances in Hematology</i> , 2013, 4, 103-117.	2.5	108
138	Results of imatinib mesylate therapy in patients with refractory or recurrent acute myeloid leukemia, high-risk myelodysplastic syndrome, and myeloproliferative disorders. <i>Cancer</i> , 2003, 97, 2760-2766.	4.1	107
139	Cytogenetic and molecular responses and outcome in chronic myelogenous leukemia. <i>Cancer</i> , 2008, 112, 837-845.	4.1	106
140	Frontline treatment of acute myeloid leukemia in adults. <i>Critical Reviews in Oncology/Hematology</i> , 2017, 110, 20-34.	4.4	105
141	Trends in chronic myeloid leukemia incidence and survival in the United States from 1975 to 2009. <i>Leukemia and Lymphoma</i> , 2013, 54, 1411-1417.	1.3	104
142	Plasma exposure of imatinib and its correlation with clinical response in the Tyrosine Kinase Inhibitor Optimization and Selectivity Trial. <i>Haematologica</i> , 2012, 97, 731-738.	3.5	103
143	Imatinib mesylate therapy may overcome the poor prognostic significance of deletions of derivative chromosome 9 in patients with chronic myelogenous leukemia. <i>Blood</i> , 2005, 105, 2281-2286.	1.4	102
144	Outcome of patients with FLT3-mutated acute myeloid leukemia in first relapse. <i>Leukemia Research</i> , 2010, 34, 752-756.	0.8	102

#	ARTICLE	IF	CITATIONS
145	Long-term follow-up results of the combination of topotecan and cytarabine and other intensive chemotherapy regimens in myelodysplastic syndrome. <i>Cancer</i> , 2006, 106, 1099-1109.	4.1	100
146	How I treat newly diagnosed chronic phase CML. <i>Blood</i> , 2012, 120, 1390-1397.	1.4	100
147	Laying the foundation for genomically-based risk assessment in chronic myeloid leukemia. <i>Leukemia</i> , 2019, 33, 1835-1850.	7.2	97
148	Pegylated interferon alfa-2a in patients with essential thrombocythaemia or polycythaemia vera: a post-hoc, median 83 month follow-up of an open-label, phase 2 trial. <i>Lancet Haematology</i> , 2017, 4, e165-e175.	4.6	96
149	Treatment-free remission with first- and second-generation tyrosine kinase inhibitors. <i>American Journal of Hematology</i> , 2019, 94, 346-357.	4.1	96
150	Significance of suboptimal response to imatinib, as defined by the European LeukemiaNet, in the long-term outcome of patients with early chronic myeloid leukemia in chronic phase. <i>Cancer</i> , 2009, 115, 3709-3718.	4.1	95
151	Sorafenib Combined with 5-azacytidine in Older Patients with Untreated FLT3-ITD Mutated Acute Myeloid Leukemia. <i>American Journal of Hematology</i> , 2018, 93, 1136-1141.	4.1	95
152	Therapeutic Options Against BCR-ABL1 T315I-Positive Chronic Myelogenous Leukemia. <i>Clinical Cancer Research</i> , 2008, 14, 4392-4399.	7.0	93
153	Superior outcome with hypomethylating therapy in patients with acute myeloid leukemia and high-risk myelodysplastic syndrome and chromosome 5 and 7 abnormalities. <i>Cancer</i> , 2009, 115, 5746-5751.	4.1	93
154	Chronic myeloid leukemia: reminiscences and dreams. <i>Haematologica</i> , 2016, 101, 541-558.	3.5	92
155	Important Therapeutic Targets in Chronic Myelogenous Leukemia. <i>Clinical Cancer Research</i> , 2007, 13, 1089-1097.	7.0	91
156	Diagnosis and Treatment of Chronic Myelomonocytic Leukemias in Adults. <i>HemaSphere</i> , 2018, 2, e150.	2.7	91
157	Imatinib mesylate therapy improves survival in patients with newly diagnosed Philadelphia chromosome-positive chronic myelogenous leukemia in the chronic phase. <i>Cancer</i> , 2003, 98, 2636-2642.	4.1	89
158	Outcome of patients with Philadelphia chromosome-positive chronic myelogenous leukemia post-imatinib mesylate failure. <i>Cancer</i> , 2007, 109, 1556-1560.	4.1	89
159	Malignancies occurring during therapy with tyrosine kinase inhibitors (TKIs) for chronic myeloid leukemia (CML) and other hematologic malignancies. <i>Blood</i> , 2011, 118, 4353-4358.	1.4	89
160	Natural history and staging of chronic myelogenous leukemia. <i>Hematology/Oncology Clinics of North America</i> , 2004, 18, 569-584.	2.2	88
161	Chemoimmunotherapy with inotuzumab ozogamicin combined with mini-hyper-CVD, with or without blinatumomab, is highly effective in patients with Philadelphia chromosome-negative acute lymphoblastic leukemia in first salvage. <i>Cancer</i> , 2018, 124, 4044-4055.	4.1	88
162	Long-term follow-up of lower dose dasatinib (50mg daily) as frontline therapy in newly diagnosed chronic phase chronic myeloid leukemia. <i>Cancer</i> , 2020, 126, 67-75.	4.1	87

#	ARTICLE	IF	CITATIONS
163	Ponatinib as first-line treatment for patients with chronic myeloid leukaemia in chronic phase: a phase 2 study. <i>Lancet Haematology</i> , 2015, 2, e376-e383.	4.6	86
164	Effects of age on prognosis with imatinib mesylate therapy for patients with Philadelphia chromosome-positive chronic myelogenous leukemia. <i>Cancer</i> , 2003, 98, 1105-1113.	4.1	85
165	Allogeneic stem cell transplantation for patients with chronic myeloid leukemia and acute lymphocytic leukemia after Bcr-Abl kinase mutation-related imatinib failure. <i>Blood</i> , 2006, 108, 1421-1423.	1.4	85
166	Phase II study of sphingosomal vincristine in patients with recurrent or refractory adult acute lymphocytic leukemia. <i>Cancer</i> , 2006, 106, 120-127.	4.1	85
167	Chronic myelogenous leukemia: A review and update of therapeutic strategies. <i>Cancer</i> , 2003, 98, 437-457.	4.1	84
168	Therapeutic advances in leukemia and myelodysplastic syndrome over the past 40 years. <i>Cancer</i> , 2008, 113, 1933-1952.	4.1	84
169	Front-Line and Salvage Therapies With Tyrosine Kinase Inhibitors and Other Treatments in Chronic Myeloid Leukemia. <i>Journal of Clinical Oncology</i> , 2011, 29, 524-531.	1.6	84
170	Treatment with a 5-day versus a 10-day schedule of decitabine in older patients with newly diagnosed acute myeloid leukaemia: a randomised phase 2 trial. <i>Lancet Haematology</i> , 2019, 6, e29-e37.	4.6	84
171	Homoharringtonine and Low-Dose Cytarabine in the Management of Late Chronic-Phase Chronic Myelogenous Leukemia. <i>Journal of Clinical Oncology</i> , 2000, 18, 3513-3521.	1.6	81
172	Clonal evolution in chronic myelogenous leukemia. <i>Hematology/Oncology Clinics of North America</i> , 2004, 18, 671-684.	2.2	78
173	Central nervous system prophylaxis in adults with acute lymphoblastic leukemia. <i>Cancer</i> , 2010, 116, 2290-2300.	4.1	77
174	Characteristics and outcome of chronic myeloid leukemia patients with F317L BCR-ABL kinase domain mutation after therapy with tyrosine kinase inhibitors. <i>Blood</i> , 2008, 112, 4839-4842.	1.4	75
175	Analysis of outcomes in adolescents and young adults with chronic myelogenous leukemia treated with upfront tyrosine kinase inhibitor therapy. <i>Haematologica</i> , 2012, 97, 1029-1035.	3.5	74
176	The rise and fall of gatekeeper mutations? The BCR-ABL1 T315I paradigm. <i>Cancer</i> , 2012, 118, 293-299.	4.1	73
177	Phase I studies of AZD1208, a proviral integration Moloney virus kinase inhibitor in solid and haematological cancers. <i>British Journal of Cancer</i> , 2018, 118, 1425-1433.	6.4	72
178	Characteristics Associated With Important Clinical End Points in Patients With Chronic Lymphocytic Leukemia at Initial Treatment. <i>Journal of Clinical Oncology</i> , 2009, 27, 1637-1643.	1.6	71
179	Results of allogeneic hematopoietic stem cell transplantation for chronic myelogenous leukemia patients who failed tyrosine kinase inhibitors after developing BCR-ABL1 kinase domain mutations. <i>Blood</i> , 2011, 117, 3641-3647.	1.4	71
180	AMN107, a novel aminopyrimidine inhibitor of p190 Bcr-Abl activation and of in vitro proliferation of Philadelphia-positive acute lymphoblastic leukemia cells. <i>Cancer</i> , 2005, 104, 1230-1236.	4.1	70

#	ARTICLE	IF	CITATIONS
181	Phase I Clinical and Pharmacokinetic Study of Oral Sapacitabine in Patients With Acute Leukemia and Myelodysplastic Syndrome. <i>Journal of Clinical Oncology</i> , 2010, 28, 285-291.	1.6	70
182	Results of triple therapy with interferon-alpha, cytarabine, and homoharringtonine, and the impact of adding imatinib to the treatment sequence in patients with Philadelphia chromosome-positive chronic myelogenous leukemia in early chronic phase. <i>Cancer</i> , 2003, 98, 888-893.	4.1	69
183	Outcome of patients with relapsed/refractory acute lymphoblastic leukemia after blinatumomab failure: No change in the level of CD19 expression. <i>American Journal of Hematology</i> , 2018, 93, 371-374.	4.1	68
184	Novel tyrosine kinase inhibitor therapy before allogeneic stem cell transplantation in patients with chronic myeloid leukemia. <i>Cancer</i> , 2007, 110, 340-344.	4.1	66
185	Allogeneic Transplantation in First Remission Improves Outcomes Irrespective of FLT3 -ITD Allelic Ratio in FLT3 -ITD Positive Acute Myelogenous Leukemia. <i>Biology of Blood and Marrow Transplantation</i> , 2016, 22, 1218-1226.	2.0	66
186	Sudden blastic transformation in patients with chronic myeloid leukemia treated with imatinib mesylate. <i>Blood</i> , 2006, 107, 480-482.	1.4	65
187	A retrospective comparison of three sequential groups of patients with Recurrent/Refractory chronic lymphocytic leukemia treated with fludarabine-based regimens. <i>Cancer</i> , 2006, 106, 337-345.	4.1	65
188	Dynamics of chronic myeloid leukemia response to long-term targeted therapy reveal treatment effects on leukemic stem cells. <i>Blood</i> , 2011, 118, 1622-1631.	1.4	65
189	Long-term molecular and cytogenetic response and survival outcomes with imatinib 400 mg, imatinib 800 mg, dasatinib, and nilotinib in patients with chronic-phase chronic myeloid leukaemia: retrospective analysis of patient data from five clinical trials. <i>Lancet Haematology</i> , 2015, 2, e118-e128.	4.6	65
190	Chronic myeloid leukaemia. <i>Lancet</i> , 2021, 398, 1914-1926.	13.7	65
191	Predictive factors for outcome and response in patients treated with second-generation tyrosine kinase inhibitors for chronic myeloid leukemia in chronic phase after imatinib failure. <i>Blood</i> , 2011, 117, 1822-1827.	1.4	64
192	Inotuzumab ozogamicin in combination with low-intensity chemotherapy (mini-HCVAD) with or without blinatumomab versus standard intensive chemotherapy (HCVAD) as frontline therapy for older patients with Philadelphia chromosome-negative acute lymphoblastic leukemia: A propensity score analysis. <i>Cancer</i> , 2019, 125, 2579-2586.	4.1	63
193	Significance of Increasing Levels of Minimal Residual Disease in Patients With Philadelphia Chromosome-Positive Chronic Myelogenous Leukemia in Complete Cytogenetic Response. <i>Journal of Clinical Oncology</i> , 2009, 27, 3659-3663.	1.6	61
194	Intolerance to tyrosine kinase inhibitors in chronic myeloid leukemia. <i>Cancer</i> , 2011, 117, 688-697.	4.1	61
195	The BCR-ABL T315I mutation compromises survival in chronic phase chronic myelogenous leukemia patients resistant to tyrosine kinase inhibitors, in a matched pair analysis. <i>Haematologica</i> , 2013, 98, 1510-1516.	3.5	61
196	Early results of lower dose dasatinib (50%mg daily) as frontline therapy for newly diagnosed chronic-phase chronic myeloid leukemia. <i>Cancer</i> , 2018, 124, 2740-2747.	4.1	61
197	Third-line therapy for chronic myeloid leukemia: current status and future directions. <i>Journal of Hematology and Oncology</i> , 2021, 14, 44.	17.0	61
198	Chronic myelogenous leukaemia with p185 BCR/ABL expression: characteristics and clinical significance. <i>British Journal of Haematology</i> , 1999, 107, 581-586.	2.5	59

#	ARTICLE	IF	CITATIONS
199	Granulocyteâ€‘colonyâ€‘stimulating factor (filgrastim) may overcome imatinibâ€‘induced neutropenia in patients with chronicâ€‘phase chronic myelogenous leukemia. <i>Cancer</i> , 2004, 100, 2592-2597.	4.1	59
200	Tyrosine Kinase Inhibitors: The First Decade. <i>Current Hematologic Malignancy Reports</i> , 2010, 5, 70-80.	2.3	58
201	Longâ€‘term outcomes in the secondâ€‘line treatment of chronic myeloid leukemia. <i>Cancer</i> , 2011, 117, 897-906.	4.1	58
202	EUTOS score is not predictive for survival and outcome in patients with early chronic phase chronic myeloid leukemia treated with tyrosine kinase inhibitors: a single institution experience. <i>Blood</i> , 2012, 119, 4524-4526.	1.4	58
203	Phase II trial of HyperCVAD and Dasatinib in patients with relapsed Philadelphia chromosome positive acute lymphoblastic leukemia or blast phase chronic myeloid leukemia. <i>American Journal of Hematology</i> , 2014, 89, 282-287.	4.1	58
204	Survival Advantage with Imatinib Mesylate Therapy in Chronic-Phase Chronic Myelogenous Leukemia (CML-CP) after IFN-Î± Failure and in Late CML-CP, Comparison with Historical Controls. <i>Clinical Cancer Research</i> , 2004, 10, 68-75.	7.0	56
205	Synthetic tumorâ€‘specific breakpoint peptide vaccine in patients with chronic myeloid leukemia and minimal residual disease. <i>Cancer</i> , 2009, 115, 3924-3934.	4.1	56
206	A Phase I/II Study of the mTOR Inhibitor Everolimus in Combination with HyperCVAD Chemotherapy in Patients with Relapsed/Refractory Acute Lymphoblastic Leukemia. <i>Clinical Cancer Research</i> , 2015, 21, 2704-2714.	7.0	56
207	The role of local radiation therapy for mediastinal disease in adults with T-cell lymphoblastic lymphoma. <i>Cancer</i> , 2002, 94, 2738-2744.	4.1	55
208	Chronic Myeloid Leukemia: Current Application of Cytogenetics and Molecular Testing for Diagnosis and Treatment. <i>Mayo Clinic Proceedings</i> , 2005, 80, 390-402.	3.0	55
209	CD56 expression predicts occurrence of CNS disease in acute lymphoblastic leukemia. <i>Leukemia Research</i> , 2002, 26, 643-649.	0.8	54
210	Biphenotypic acute leukaemia: a case series. <i>British Journal of Haematology</i> , 2007, 138, 213-216.	2.5	54
211	HCVAD plus imatinib or dasatinib in lymphoid blastic phase chronic myeloid leukemia. <i>Cancer</i> , 2014, 120, 373-380.	4.1	54
212	Cardiovascular and pulmonary adverse events in patients treated with <i><sc>BCR</sc>â€‘<sc>ABL</sc></i> inhibitors: Data from the <sc>FDA</sc> Adverse Event Reporting System. <i>American Journal of Hematology</i> , 2015, 90, E66-72.	4.1	54
213	Central Nervous System Involvement in Adult Acute Lymphocytic Leukemia. <i>Hematology/Oncology Clinics of North America</i> , 2001, 15, 145-162.	2.2	53
214	Phase 1 study of lonafarnib (SCH 66336) and imatinib mesylate in patients with chronic myeloid leukemia who have failed prior singleâ€‘agent therapy with imatinib. <i>Cancer</i> , 2007, 110, 1295-1302.	4.1	53
215	Survival outcomes for clonal evolution in chronic myeloid leukemia patients on second generation tyrosine kinase inhibitor therapy. <i>Cancer</i> , 2010, 116, 2673-2681.	4.1	51
216	New Targeted Approaches in Chronic Myeloid Leukemia. <i>Journal of Clinical Oncology</i> , 2005, 23, 6316-6324.	1.6	50

#	ARTICLE	IF	CITATIONS
217	Optimizing management of ruxolitinib in patients with myelofibrosis: the need for individualized dosing. <i>Journal of Hematology and Oncology</i> , 2013, 6, 79.	17.0	50
218	Treatment selection after imatinib resistance in chronic myeloid leukemia. <i>Targeted Oncology</i> , 2009, 4, 3-10.	3.6	49
219	Impact of Treatment End Point Definitions on Perceived Differences in Long-Term Outcome With Tyrosine Kinase Inhibitor Therapy in Chronic Myeloid Leukemia. <i>Journal of Clinical Oncology</i> , 2011, 29, 3173-3178.	1.6	49
220	Incidence of and risk factors for involvement of the central nervous system in acute myeloid leukemia. <i>Leukemia and Lymphoma</i> , 2015, 56, 1392-1397.	1.3	48
221	Evolution of Therapies for Chronic Myelogenous Leukemia. <i>Cancer Journal (Sudbury, Mass )</i> , 2011, 17, 465-476.	2.0	47
222	Advanced-phase chronic myeloid leukemia. <i>Seminars in Hematology</i> , 2003, 40, 79-86.	3.4	46
223	Molecular basis explanation for imatinib resistance of BCR-ABL due to T315I and P-loop mutations from molecular dynamics simulations. <i>Cancer</i> , 2008, 112, 1744-1753.	4.1	46
224	Chronic Myeloid Leukemia: Mechanisms of Resistance and Treatment. <i>Hematology/Oncology Clinics of North America</i> , 2011, 25, 981-995.	2.2	46
225	Immune modulation of minimal residual disease in early chronic phase chronic myelogenous leukemia. <i>Cancer</i> , 2011, 117, 572-580.	4.1	46
226	A pilot study of imatinib, low-dose cytarabine and idarubicin for patients with chronic myeloid leukemia in myeloid blast phase. <i>Leukemia and Lymphoma</i> , 2007, 48, 283-289.	1.3	45
227	Phase 1 study of INNO-406, a dual Abl/Lyn kinase inhibitor, in Philadelphia chromosome-positive leukemias after imatinib resistance or intolerance. <i>Cancer</i> , 2010, 116, 2665-2672.	4.1	45
228	Tyrosine kinase inhibitors in acute and chronic leukemias. <i>Expert Opinion on Pharmacotherapy</i> , 2012, 13, 927-938.	1.8	44
229	Targeting the Kinase Activity of the BCR-ABL Fusion Protein in Patients with Chronic Myeloid Leukemia. <i>Current Molecular Medicine</i> , 2005, 5, 615-623.	1.3	41
230	Optimizing therapy for patients with chronic myelogenous leukemia in chronic phase. <i>Cancer</i> , 2010, 116, 1419-1430.	4.1	40
231	Progress in Acute Myeloid Leukemia. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2015, 15, 139-151.	0.4	40
232	New agents in acute myeloid leukemia and other myeloid disorders. <i>Cancer</i> , 2004, 100, 441-454.	4.1	39
233	Dynamics and management of cytopenias associated with dasatinib therapy in patients with chronic myeloid leukemia in chronic phase after imatinib failure. <i>Cancer</i> , 2009, 115, 3935-3943.	4.1	39
234	Synergistic effects of p53 activation via MDM2 inhibition in combination with inhibition of Bcl-2 or Bcr-Abl in CD34+ proliferating and quiescent chronic myeloid leukemia blast crisis cells. <i>Oncotarget</i> , 2015, 6, 30487-30499.	1.8	39

#	ARTICLE	IF	CITATIONS
235	Improving outcomes for patients with acute myeloid leukemia in first relapse: A single center experience. <i>American Journal of Hematology</i> , 2015, 90, 27-30.	4.1	38
236	Clinical impact of dose reductions and interruptions of second-generation tyrosine kinase inhibitors in patients with chronic myeloid leukaemia. <i>British Journal of Haematology</i> , 2010, 150, 303-312.	2.5	37
237	<sc>SL</sc>401 and <sc>SL</sc>501, targeted therapeutics directed at the interleukin-3 receptor, inhibit the growth of leukaemic cells and stem cells in advanced phase chronic myeloid leukaemia. <i>British Journal of Haematology</i> , 2014, 166, 862-874.	2.5	37
238	BCR-ABL fusion transcript types and levels and their interaction with secondary genetic changes in determining the phenotype of Philadelphia chromosome-positive leukemias. <i>Blood</i> , 2008, 112, 5190-5192.	1.4	36
239	A phase 1 study of a farnesyltransferase inhibitor, tipifarnib, combined with idarubicin and cytarabine for patients with newly diagnosed acute myeloid leukemia and high-risk myelodysplastic syndrome. <i>Cancer</i> , 2011, 117, 1236-1244.	4.1	36
240	Reverse phase protein array profiling reveals distinct proteomic signatures associated with chronic myeloid leukemia progression and with chronic phase in the CD34-positive compartment. <i>Cancer</i> , 2012, 118, 5283-5292.	4.1	36
241	Phase I Dose-Escalation Trial of SB1518, a Novel JAK2/FLT3 Inhibitor, in Acute and Chronic Myeloid Diseases, Including Primary or Post-Essential Thrombocythemia/ Polycythemia Vera Myelofibrosis.. <i>Blood</i> , 2009, 114, 3905-3905.	1.4	36
242	Prognostic factors for outcome in patients with refractory and relapsed acute lymphocytic leukemia treated with inotuzumab ozogamicin, a <sc>CD</sc>22 monoclonal antibody. <i>American Journal of Hematology</i> , 2015, 90, 193-196.	4.1	35
243	Phase I Study of Cloretazine (VNP40101M), a Novel Sulfonylhydrazine Alkylating Agent, Combined with Cytarabine in Patients with Refractory Leukemia. <i>Clinical Cancer Research</i> , 2005, 11, 7817-7824.	7.0	34
244	A Multinational Study of Health State Preference Values Associated with Chronic Myelogenous Leukemia. <i>Value in Health</i> , 2010, 13, 103-111.	0.3	34
245	Twice-Daily Fludarabine and Cytarabine Combination With or Without Gentuzumab Ozogamicin is Effective in Patients With Relapsed/Refractory Acute Myeloid Leukemia, High-Risk Myelodysplastic Syndrome, and Blast- Phase Chronic Myeloid Leukemia. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2012, 12, 244-251.	0.4	34
246	Chronic Myeloid Leukemia: Overview of New Agents and Comparative Analysis. <i>Current Treatment Options in Oncology</i> , 2013, 14, 127-143.	3.0	34
247	Phase I Evaluation of a 40-kDa Branched-Chain Long-Acting Pegylated IFN-2a With and Without Cytarabine in Patients with Chronic Myelogenous Leukemia. <i>Clinical Cancer Research</i> , 2005, 11, 6247-6255.	7.0	33
248	Dasatinib for the treatment of Philadelphia chromosome-positive leukaemias. <i>Expert Opinion on Investigational Drugs</i> , 2007, 16, 679-687.	4.1	33
249	Practical issues surrounding the explosion of tyrosine kinase inhibitors for the management of chronic myeloid leukemia. <i>Blood Reviews</i> , 2014, 28, 179-187.	5.7	33
250	<sc>S</sc>ignificance of recurrence of minimal residual disease detected by multi-parameter flow cytometry in patients with acute lymphoblastic leukemia in morphological remission. <i>American Journal of Hematology</i> , 2017, 92, 279-285.	4.1	32
251	Prognostic significance of baseline <i>FLT3</i> mutant allele level in acute myeloid leukemia treated with intensive chemotherapy with/without sorafenib. <i>American Journal of Hematology</i> , 2019, 94, 984-991.	4.1	32
252	Advances in the Therapy of Chronic Idiopathic Myelofibrosis. <i>Oncologist</i> , 2006, 11, 929-943.	3.7	31

#	ARTICLE	IF	CITATIONS
253	Triptolide induces cell death independent of cellular responses to imatinib in blast crisis chronic myelogenous leukemia cells including quiescent CD34+ primitive progenitor cells. <i>Molecular Cancer Therapeutics</i> , 2009, 8, 2509-2516.	4.1	31
254	Chronic Myeloid Leukemia in the Tyrosine Kinase Inhibitor Era: What Is the "Best" Therapy?. <i>Current Oncology Reports</i> , 2010, 12, 302-313.	4.0	31
255	Monitoring molecular response in chronic myeloid leukemia. <i>Cancer</i> , 2011, 117, 1113-1122.	4.1	31
256	Considerations in the Management of Patients With Philadelphia Chromosome-Positive Chronic Myeloid Leukemia Receiving Tyrosine Kinase Inhibitor Therapy. <i>Journal of Clinical Oncology</i> , 2011, 29, 1512-1516.	1.6	31
257	Activity of 9-nitro-camptothecin, an oral topoisomerase I inhibitor, in myelodysplastic syndrome and chronic myelomonocytic leukemia. <i>Cancer</i> , 2006, 107, 1525-1529.	4.1	30
258	Patterns of Molecular Response to and Relapse After Combination of Sorafenib, Idarubicin, and Cytarabine in Patients With FLT3 Mutant Acute Myeloid Leukemia. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2011, 11, 361-366.	0.4	30
259	A Phase 1/2 Study of SKI-606, a Dual Inhibitor of Src and Abl Kinases, in Adult Patients with Philadelphia Chromosome Positive (Ph+) Chronic Myelogenous Leukemia (CML) or Acute Lymphocytic Leukemia (ALL) Relapsed, Refractory or Intolerant of Imatinib.. <i>Blood</i> , 2006, 108, 168-168.	1.4	30
260	Nilotinib for the treatment of chronic myeloid leukemia: An evidence-based review. <i>Core Evidence</i> , 2010, 4, 207.	4.7	29
261	Stem cell transplantation for patients with chronic myeloid leukemia resistant to tyrosine kinase inhibitors with BCR-ABL kinase domain mutation T315I. <i>Cancer</i> , 2010, 116, 3631-3637.	4.1	29
262	A Phase I Study of XL019, a Selective JAK2 Inhibitor, in Patients with Primary Myelofibrosis, Post-Polycythemia Vera, or Post-Essential Thrombocythemia Myelofibrosis. <i>Blood</i> , 2008, 112, 98-98.	1.4	29
263	New Targeted Therapies for Chronic Myelogenous Leukemia: Opportunities to Overcome Imatinib Resistance. <i>Seminars in Hematology</i> , 2007, 44, 25-31.	3.4	28
264	Omacetaxine mepesuccinate in patients with advanced chronic myeloid leukemia with resistance or intolerance to tyrosine kinase inhibitors. <i>Leukemia and Lymphoma</i> , 2015, 56, 120-127.	1.3	28
265	Phase I/II study of dasatinib in combination with decitabine in patients with accelerated or blast phase chronic myeloid leukemia. <i>American Journal of Hematology</i> , 2020, 95, 1288-1295.	4.1	28
266	INCB018424, an Oral, Selective JAK2 Inhibitor, Shows Significant Clinical Activity in a Phase I/II Study in Patients with Primary Myelofibrosis (PMF) and Post Polycythemia Vera/Essential Thrombocythemia Myelofibrosis (Post-PV/ET MF).. <i>Blood</i> , 2007, 110, 558-558.	1.4	28
267	Emerging Safety Issues with Imatinib and Other Abl Tyrosine Kinase Inhibitors. <i>Clinical Lymphoma and Myeloma</i> , 2007, 7, S105-S112.	1.4	27
268	Sustained complete molecular response after imatinib discontinuation in a patient with chronic myeloid leukemia not previously exposed to interferon alpha. <i>Leukemia and Lymphoma</i> , 2008, 49, 1399-1402.	1.3	27
269	Investigational FMS-like tyrosine kinase 3 inhibitors in treatment of acute myeloid leukemia. <i>Expert Opinion on Investigational Drugs</i> , 2014, 23, 943-954.	4.1	27
270	Bone marrow necrosis in acute leukemia: Clinical characteristic and outcome. <i>American Journal of Hematology</i> , 2015, 90, 769-773.	4.1	27



#	ARTICLE	IF	CITATIONS
271	Novel tyrosine kinase inhibitors in chronic myelogenous leukemia. <i>Current Opinion in Oncology</i> , 2006, 18, 578-583.	2.4	26
272	Epigenetic Therapy With Hydralazine and Magnesium Valproate Reverses Imatinib Resistance in Patients With Chronic Myeloid Leukemia. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2012, 12, 207-212.	0.4	26
273	A randomized study of 2 dose levels of intravenous clofarabine in the treatment of patients with higher-risk myelodysplastic syndrome. <i>Cancer</i> , 2012, 118, 722-728.	4.1	26
274	Cardiovascular toxicity of tyrosine kinase inhibitors. <i>Expert Opinion on Drug Safety</i> , 2013, 12, 687-696.	2.4	26
275	Clinical Safety and Efficacy of Nilotinib or Dasatinib in Patients With Newly Diagnosed Chronic-Phase Chronic Myelogenous Leukemia and Pre-Existing Liver and/or Renal Dysfunction. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2016, 16, 152-162.	0.4	25
276	The early achievement of measurable residual disease negativity in the treatment of adults with Philadelphia-negative B-cell acute lymphoblastic leukemia is a strong predictor for survival. <i>American Journal of Hematology</i> , 2020, 95, 144-150.	4.1	25
277	Significance of myelofibrosis in early chronic-phase, chronic myelogenous leukemia on imatinib mesylate therapy. <i>Cancer</i> , 2005, 104, 777-780.	4.1	24
278	BCR-ABL Truncation due to Premature Translation Termination as a Mechanism of Resistance to Kinase Inhibitors. <i>Acta Haematologica</i> , 2009, 121, 27-31.	1.4	24
279	Failure to achieve a complete hematologic response at the time of a major cytogenetic response with second-generation tyrosine kinase inhibitors is associated with a poor prognosis among patients with chronic myeloid leukemia in accelerated or blast phase. <i>Blood</i> , 2009, 113, 5058-5063.	1.4	24
280	Outcome After Failure of Second Generation Tyrosine Kinase Inhibitors Treatment As First-line Therapy for Patients With Chronic Myeloid Leukemia. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2013, 13, 477-484.	0.4	24
281	Optimizing Outcomes for Patients With Advanced Disease in Chronic Myelogenous Leukemia. <i>Seminars in Oncology</i> , 2008, 35, S1-S17.	2.2	23
282	Current patient management of chronic myeloid leukemia in Latin America. <i>Cancer</i> , 2010, 116, 4991-5000.	4.1	23
283	Analysis of the potential effect of ponatinib on the QTc interval in patients with refractory hematological malignancies. <i>Cancer Chemotherapy and Pharmacology</i> , 2013, 71, 1599-1607.	2.3	23
284	A Phase I Evaluation of TG101348, a Selective JAK2 Inhibitor, in Myelofibrosis: Clinical Response Is Accompanied by Significant Reduction in JAK2V617F Allele Burden. <i>Blood</i> , 2009, 114, 755-755.	1.4	23
285	New Strategies in Chronic Myeloid Leukemia. <i>International Journal of Hematology</i> , 2006, 83, 289-293.	1.6	22
286	Burkitt Lymphoma and Atypical Burkitt or Burkitt-like Lymphoma: Should These be Treated as Different Diseases?. <i>Current Hematologic Malignancy Reports</i> , 2011, 6, 58-66.	2.3	22
287	Role of Tyrosine Kinase Inhibitors in the Management of Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia. <i>Current Hematologic Malignancy Reports</i> , 2011, 6, 187-194.	2.3	22
288	Allogeneic Hematopoietic Cell Transplantation for Advanced Polycythemia Vera and Essential Thrombocythemia. <i>Biology of Blood and Marrow Transplantation</i> , 2012, 18, 1446-1454.	2.0	22

#	ARTICLE	IF	CITATIONS
289	Targeted Therapies in Hematology and Their Impact on Patient Care: Chronic and Acute Myeloid Leukemia. <i>Seminars in Hematology</i> , 2013, 50, 271-283.	3.4	22
290	Phase 1 dose-finding study of rebastinib (DCC-2036) in patients with relapsed chronic myeloid leukemia and acute myeloid leukemia. <i>Haematologica</i> , 2017, 102, 519-528.	3.5	22
291	Nilotinib: a phenylamino-pyrimidine derivative with activity against BCR-ABL, KIT and PDGFR kinases. <i>Future Oncology</i> , 2008, 4, 611-621.	2.4	21
292	Imatinib front-line therapy is safe and effective in patients with chronic myelogenous leukemia with pre-existing liver and/or renal dysfunction. <i>Cancer</i> , 2010, 116, 3152-3159.	4.1	21
293	Current event-free survival after sequential tyrosine kinase inhibitor therapy for chronic myeloid leukemia. <i>Cancer</i> , 2011, 117, 327-335.	4.1	21
294	The role of ponatinib in Philadelphia chromosome-positive acute lymphoblastic leukemia. <i>Expert Review of Anticancer Therapy</i> , 2015, 15, 365-373.	2.4	21
295	Phase II study of methotrexate, vincristine, pegylated asparaginase, and dexamethasone (MOAD) in patients with relapsed/refractory acute lymphoblastic leukemia. <i>American Journal of Hematology</i> , 2015, 90, 120-124.	4.1	21
296	How to manage CML patients with comorbidities. <i>Blood</i> , 2020, 136, 2507-2512.	1.4	21
297	Response to therapy is independently associated with survival prolongation in chronic myelogenous leukemia in the blastic phase. <i>Cancer</i> , 2001, 92, 2501-2507.	4.1	20
298	Targeting ABL and SRC kinases in chronic myeloid leukemia: experience with dasatinib. <i>Future Oncology</i> , 2006, 2, 655-665.	2.4	20
299	Third-Generation Tyrosine Kinase Inhibitors and Beyond. <i>Seminars in Hematology</i> , 2010, 47, 371-380.	3.4	20
300	The Achievement of a 3-Month Complete Cytogenetic Response to Second-Generation Tyrosine Kinase Inhibitors Predicts Survival in Patients With Chronic Phase Chronic Myeloid Leukemia After Imatinib Failure. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2013, 13, 302-306.	0.4	20
301	Outcomes with lower intensity therapy in TP53-mutated acute myeloid leukemia. <i>Leukemia and Lymphoma</i> , 2018, 59, 2238-2241.	1.3	20
302	Plasma RNA as an alternative to cells for monitoring molecular response in patients with chronic myeloid leukemia. <i>Haematologica</i> , 2007, 92, 170-175.	3.5	19
303	Anthracycline dose intensification in adult acute lymphoblastic leukemia. <i>Cancer</i> , 2010, 116, 4580-4589.	4.1	19
304	Chronic Myeloid Leukemia in Adolescents and Young Adults: Patient Characteristics, Outcomes and Review of the Literature. <i>Acta Haematologica</i> , 2014, 132, 298-306.	1.4	19
305	Analysis of 2013 European LeukaemiaNet (ELN) responses in chronic phase CML across four frontline TKI modalities and impact on clinical outcomes. <i>British Journal of Haematology</i> , 2016, 173, 114-126.	2.5	19
306	Outcome of patients with chronic myeloid leukemia with multiple ABL1 kinase domain mutations receiving tyrosine kinase inhibitor therapy. <i>Haematologica</i> , 2011, 96, 918-924.	3.5	18

#	ARTICLE	IF	CITATIONS
307	Experimental therapeutics for patients with myeloproliferative neoplasias. <i>Cancer</i> , 2011, 117, 662-676.	4.1	18
308	Dynamics of chronic myeloid leukemia response to dasatinib, nilotinib, and high-dose imatinib. <i>Haematologica</i> , 2014, 99, 1701-1709.	3.5	18
309	Omacetaxine Mepesuccinate for Chronic Myeloid Leukemia. <i>Expert Review of Hematology</i> , 2016, 9, 419-424.	2.2	18
310	<i>TP53</i> mutation does not confer a poor outcome in adult patients with acute lymphoblastic leukemia who are treated with frontline hyper- <i>CVAD</i> -based regimens. <i>Cancer</i> , 2017, 123, 3717-3724.	4.1	18
311	Omacetaxine mepesuccinate (synribo) – newly launched in chronic myeloid leukemia. <i>Expert Opinion on Pharmacotherapy</i> , 2013, 14, 1977-1986.	1.8	17
312	The Society for Immunotherapy of Cancer consensus statement on immunotherapy for the treatment of hematologic malignancies: multiple myeloma, lymphoma, and acute leukemia. , 2016, 4, 90.		17
313	Overcoming drug resistance in chronic myeloid leukemia. <i>Current Opinion in Hematology</i> , 2006, 13, 79-86.	2.5	16
314	New developments in the treatment of chronic myeloid leukemia and Philadelphia-positive acute lymphoblastic leukemia. <i>Leukemia and Lymphoma</i> , 2011, 52, 81-91.	1.3	16
315	Pilot Study of Bortezomib for Patients With Imatinib-Refractory Chronic Myeloid Leukemia in Chronic or Accelerated Phase. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2011, 11, 355-360.	0.4	16
316	Prognostic impact of deletions of derivative chromosome 9 in patients with chronic myelogenous leukemia treated with nilotinib or dasatinib. <i>Cancer</i> , 2011, 117, 5085-5093.	4.1	16
317	Chronic myeloid leukemia: sequencing of TKI therapies. <i>Hematology American Society of Hematology Education Program</i> , 2016, 2016, 164-169.	2.5	16
318	Evaluation of cardiovascular ischemic event rates in dasatinib-treated patients using standardized incidence ratios. <i>Annals of Hematology</i> , 2017, 96, 1303-1313.	1.8	16
319	Chronic Myeloid Leukemia and Second-Generation Tyrosine Kinase Inhibitors: When, How, and Which One?. <i>Seminars in Hematology</i> , 2010, 47, 344-353.	3.4	15
320	The Clinical Significance of Achieving Different Levels of Cytogenetic Response in Patients With Chronic Phase Chronic Myeloid Leukemia After Failure to Front-Line Therapy: Is Complete Cytogenetic Response the Only Desirable Endpoint?. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2011, 11, 421-426.	0.4	15
321	Mutant BCR-ABL clones in chronic myeloid leukemia. <i>Haematologica</i> , 2011, 96, 347-349.	3.5	15
322	Phase I and Extension Study of Clofarabine Plus Cyclophosphamide in Patients With Relapsed/Refractory Acute Lymphoblastic Leukemia. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2014, 14, 231-238.	0.4	15
323	BCR-ABL Mutations in Chronic Myeloid Leukemia Treated With Tyrosine Kinase Inhibitors and Impact on Survival. <i>Cancer Investigation</i> , 2015, 33, 451-458.	1.3	15
324	Design and rationale for the life after stopping tyrosine kinase inhibitors (LAST) study, a prospective, single-group longitudinal study in patients with chronic myeloid leukemia. <i>BMC Cancer</i> , 2018, 18, 359.	2.6	15

#	ARTICLE	IF	CITATIONS
325	The effect of eltrombopag in managing thrombocytopenia associated with tyrosine kinase therapy in patients with chronic myeloid leukemia and myelofibrosis. <i>Haematologica</i> , 2021, 106, 2853-2858.	3.5	15
326	Long-term prognostic impact of the use of erythropoietic-stimulating agents in patients with chronic myeloid leukemia in chronic phase treated with imatinib. <i>Cancer</i> , 2011, 117, 982-991.	4.1	14
327	Treatment options for chronic myeloid leukemia. <i>Expert Opinion on Pharmacotherapy</i> , 2012, 13, 815-828.	1.8	14
328	Predicting Outcomes in Patients With Chronic Myeloid Leukemia at Any Time During Tyrosine Kinase Inhibitor Therapy. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2014, 14, 327-334.e8.	0.4	14
329	Systematic review and meta-analysis of standard-dose imatinib vs. high-dose imatinib and second generation tyrosine kinase inhibitors for chronic myeloid leukemia. <i>Journal of Cancer Research and Clinical Oncology</i> , 2017, 143, 1311-1318.	2.5	14
330	Review of New-Generation Tyrosine Kinase Inhibitors for Chronic Myeloid Leukemia. <i>Current Oncology Reports</i> , 2021, 23, 91.	4.0	14
331	Rapid clonal shifts in response to kinase inhibitor therapy in chronic myelogenous leukemia are identified by quantitation mutation assays. <i>Cancer Science</i> , 2010, 101, 2005-2010.	3.9	13
332	Experience with rituximab immunotherapy as an early intervention in patients with Rai stage 0 to II chronic lymphocytic leukemia. <i>Cancer</i> , 2011, 117, 3182-3186.	4.1	13
333	Impact of achievement of complete cytogenetic response on outcome in patients with myelodysplastic syndromes treated with hypomethylating agents. <i>American Journal of Hematology</i> , 2017, 92, 351-358.	4.1	13
334	Nilotinib: a novel Bcr-Abl tyrosine kinase inhibitor for the treatment of leukemias. <i>Expert Opinion on Investigational Drugs</i> , 2008, 17, 1127-1136.	4.1	12
335	Imatinib mesylate therapy for polycythemia vera: final result of a phase II study initiated in 2001. <i>International Journal of Hematology</i> , 2009, 90, 58-63.	1.6	12
336	How to manage CML patients with comorbidities. <i>Hematology American Society of Hematology Education Program</i> , 2020, 2020, 237-242.	2.5	12
337	Development and targeted use of nilotinib in chronic myeloid leukemia. <i>Drug Design, Development and Therapy</i> , 2008, 2, 233.	4.3	11
338	Chronic myeloid leukemia in the tyrosine kinase inhibitor era: What is the best therapy?. <i>Current Oncology Reports</i> , 2009, 11, 337-345.	4.0	11
339	Dasatinib for the treatment of Philadelphia chromosome-positive leukemias. <i>Expert Opinion on Pharmacotherapy</i> , 2012, 13, 2381-2395.	1.8	11
340	Treatment patterns and deep molecular response in chronic phase “ chronic myeloid leukemia patients treated with second-line nilotinib or dasatinib: a multi-country retrospective chart review study. <i>Leukemia and Lymphoma</i> , 2020, 61, 98-107.	1.3	11
341	Treatment of Philadelphia chromosome-positive chronic myelogenous leukemia with weekly polyethylene glycol formulation of interferon-alpha-2b and low-dose cytosine arabinoside. <i>Cancer</i> , 2003, 97, 3010-3016.	4.1	10
342	The clinical challenge of imatinib resistance in chronic myeloid leukemia: emerging strategies with new targeted agents. <i>Targeted Oncology</i> , 2006, 1, 186-196.	3.6	10

#	ARTICLE	IF	CITATIONS
343	Tailoring tyrosine kinase inhibitor therapy to tackle specific BCR-ABL1 mutant clones. <i>Leukemia Research</i> , 2008, 32, 1313-1316.	0.8	10
344	Uncommon BCR-ABL kinase domain mutations in kinase inhibitor-resistant chronic myelogenous leukemia and Ph+ acute lymphoblastic leukemia show high rates of regression, suggesting weak selective effects. <i>Blood</i> , 2010, 115, 5428-5429.	1.4	10
345	Salvage Therapy Outcomes in a Historical Cohort of Patients With Relapsed or Refractory Acute Myeloid Leukemia. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2020, 20, e871-e882.	0.4	10
346	Outcome of Treatment of Chronic Myeloid Leukemia With Second-Generation Tyrosine Kinase Inhibitors After Imatinib Failure. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2011, 11, S101-S110.	0.4	9
347	Acute myeloid leukemia: advancing clinical trials and promising therapeutics. <i>Expert Review of Hematology</i> , 2016, 9, 433-445.	2.2	9
348	New agents in the treatment of acute lymphocytic leukaemia. <i>Best Practice and Research in Clinical Haematology</i> , 2002, 15, 771-790.	1.7	8
349	Retrospective Analysis of Prognostic Factors Associated With Response and Overall Survival by Baseline Marrow Blast Percentage in Patients With Myelodysplastic Syndromes Treated With Decitabine. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2013, 13, 592-596.	0.4	8
350	Therapeutic options for patients with clonal and idiopathic hypereosinophilia. <i>Expert Opinion on Investigational Drugs</i> , 2008, 17, 1039-1050.	4.1	7
351	Timing of allogeneic hematopoietic cell transplantation (alloHCT) for chronic myeloid leukemia (CML) patients. <i>Leukemia and Lymphoma</i> , 2020, 61, 2811-2820.	1.3	7
352	Current Perspectives on the Treatment of Patients with Chronic Myeloid Leukemia: An Individualized Approach to Treatment. <i>Cancer Journal (Sudbury, Mass )</i> , 2007, 13, 357-365.	2.0	6
353	Dasatinib for the treatment of chronic myeloid leukemia. <i>Expert Review of Hematology</i> , 2011, 4, 253-260.	2.2	6
354	Does pretreatment fluorescence in situ hybridization for BCR-ABL predict imatinib-associated hematologic toxicity in chronic myeloid leukemia?. <i>Leukemia and Lymphoma</i> , 2011, 52, 1010-1016.	1.3	6
355	Pleural Effusion in Patients (pts) with Chronic Myelogenous Leukemia (CML) Treated with Dasatinib after Imatinib Failure.. <i>Blood</i> , 2006, 108, 2164-2164.	1.4	6
356	CML: the good, the better, and the difficult choices. <i>Blood</i> , 2012, 120, 3866-3867.	1.4	5
357	The Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immunotherapy for the treatment of acute leukemia. , 2020, 8, e000810.		5
358	Management of Patients with Newly Diagnosed Chronic Myeloid Leukemia: Opportunities and Challenges. <i>Clinical Lymphoma and Myeloma</i> , 2007, 7, S51-S57.	1.4	4
359	Nilotinib for the treatment of Philadelphia-chromosome-positive chronic myeloid leukemia. <i>Expert Opinion on Pharmacotherapy</i> , 2010, 11, 3065-3072.	1.8	4
360	Molecular Resistance: An Early Indicator for Treatment Change?. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2012, 12, 79-87.	0.4	4

#	ARTICLE	IF	CITATIONS
361	Phase III Study of Bendamustine in Patients With Acute Leukemia and High Risk Myelodysplastic Syndrome. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2012, 12, 197-200.	0.4	4
362	Second-generation tyrosine kinase inhibitors as therapy for chronic myeloid leukemia. <i>Current Hematologic Malignancy Reports</i> , 2007, 2, 83-88.	2.3	3
363	Complexity of BCR-ABL kinase domain mutations during the course of therapy with tyrosine kinase inhibitors in chronic myeloid leukemia. <i>American Journal of Hematology</i> , 2009, 84, 256-257.	4.1	3
364	Optimizing First-Line Therapy for Patients With Chronic Myeloid Leukemia. <i>Seminars in Hematology</i> , 2009, 46, S5-S10.	3.4	2
365	Decitabine Can Be Safely Reduced After Achievement of Best Objective Response in Patients With Myelodysplastic Syndrome. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2013, 13, S289-S294.	0.4	2
366	Molecular Biology and Cytogenetics of Chronic Myeloid Leukemia. , 2018, , 29-47.		2
367	Outcomes of patients with chronic phase chronic myeloid leukemia (CML-CP) after discontinuation of frontline ponatinib therapy. <i>Leukemia and Lymphoma</i> , 2019, 60, 3172-3180.	1.3	2
368	Chronic Myeloid Leukemia. , 2020, , 1836-1849.e2.		2
369	Optimal initial therapy for patients with newly diagnosed chronic myeloid leukemia in chronic phase. <i>Current Opinion in Internal Medicine</i> , 2007, 6, 268-274.	1.5	1
370	New approaches to the management of Philadelphia chromosome-positive acute lymphocytic leukemia. <i>Current Hematologic Malignancy Reports</i> , 2007, 2, 183-189.	2.3	1
371	Secondary myelodysplastic syndrome in a patient with Philadelphia-positive acute lymphoblastic leukemia after achieving a major molecular response with hyperCVAD plus imatinib mesylate. <i>Leukemia Research</i> , 2008, 32, 1468-1471.	0.8	1
372	ASH 2009 meeting report-Top 10 clinically oriented abstracts in acute leukemia. <i>American Journal of Hematology</i> , 2010, 85, 277-280.	4.1	1
373	Towards a Cure for Chronic Myeloid Leukemia: Are We There Yet?. <i>Seminars in Hematology</i> , 2010, 47, 299-301.	3.4	1
374	Molecular Biology and Cytogenetics of Chronic Myeloid Leukemia. , 2013, , 29-44.		1
375	Chronic Myeloid Leukemia. , 2014, , 1944-1957.e2.		1
376	Biology of Chronic and Acute Myeloid Leukemia. , 2008, , 371-383.		1
377	The significance of major and stable molecular responses in chronic myeloid leukemia in the tyrosine kinase inhibitor era. <i>Revista Brasileira De Hematologia E Hemoterapia</i> , 2011, 33, 455-460.	0.7	1
378	Comments on the Hammersmith policy. <i>Seminars in Hematology</i> , 2003, 40, 105-106.	3.4	0

#	ARTICLE	IF	CITATIONS
379	Investigational Agents in Myeloid Disorders. <i>Advances in Pharmacology</i> , 2004, 51, 59-97.	2.0	0
380	The daunting task of modeling response to imatinib therapy in patients with chronic myelogenous leukemia. <i>Leukemia and Lymphoma</i> , 2007, 48, 802-804.	1.3	0
381	Scrotal Edema Associated with the Use of Dasatinib in Patients with Chronic Myeloid Leukemia. <i>Clinical Leukemia</i> , 2007, 1, 357-358.	0.2	0
382	Chronic myeloid leukemia: The race is yet to be won. <i>Cmaj</i> , 2012, 184, 857-858.	2.0	0
383	Phase II trials of tyrosine kinase inhibitors in the treatment of chronic myeloid leukemia. <i>Expert Opinion on Orphan Drugs</i> , 2013, 1, 607-623.	0.8	0
384	Novel treatment options for acute myelocytic leukemia. <i>Clinical Investigation</i> , 2013, 3, 979-990.	0.0	0
385	New Tool for Monitoring Molecular Response in Patients With Chronic Myeloid Leukemia. <i>Applied Immunohistochemistry and Molecular Morphology</i> , 2019, 27, 33-39.	1.2	0
386	CML Therapy: A Focus on Second- and Third-Generation Tyrosine Kinase Inhibitors. <i>Hematologic Malignancies</i> , 2021, , 61-76.	0.2	0
387	Chronic Myeloid Leukemia: Pathophysiology and Therapeutics. , 2010, , 139-153.		0